Get the Stockscreener App
36.17
0.90%
-0.33
Exelixis Inc stock is traded at $36.17, with a volume of 1.87M.
It is down -0.90% in the last 24 hours and up +2.35% over the past month.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
See More
Previous Close:
$36.50
Open:
$36.58
24h Volume:
1.87M
Relative Volume:
0.74
Market Cap:
$10.91B
Revenue:
$2.08B
Net Income/Loss:
$466.92M
P/E Ratio:
23.19
EPS:
1.56
Net Cash Flow:
$404.94M
1W Performance:
-8.66%
1M Performance:
+2.35%
6M Performance:
-0.22%
1Y Performance:
+66.22%
1-Day Range:
$36.16
$37.39
1-Week Range:
$34.90
$40.26
52-Week Range:
$20.14
$40.26
Exelixis Inc Stock (EXEL) Company Profile
Name
Exelixis Inc
Sector
Industry
Phone
(650) 837-7000
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
36.17 | 10.91B | 2.08B | 466.92M | 404.94M | 1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-27-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-24-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-16-24 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-19-24 | Initiated | UBS | Neutral |
| Apr-11-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-23 | Initiated | BTIG Research | Buy |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Sep-26-23 | Initiated | H.C. Wainwright | Buy |
| Aug-22-23 | Reiterated | Oppenheimer | Outperform |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-11-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Resumed | Piper Sandler | Overweight |
| Mar-09-23 | Initiated | Wells Fargo | Overweight |
| Jan-26-23 | Initiated | Credit Suisse | Outperform |
| Oct-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-03-21 | Resumed | Jefferies | Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-21 | Initiated | H.C. Wainwright | Buy |
| May-18-21 | Resumed | Goldman | Sell |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Mar-18-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-17-18 | Initiated | Goldman | Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Underweight |
| May-11-18 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-16-17 | Reiterated | SunTrust | Buy |
| Sep-22-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-12-17 | Reiterated | Needham | Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Mar-31-17 | Initiated | Needham | Buy |
| Mar-16-17 | Initiated | Oppenheimer | Perform |
| Feb-28-17 | Downgrade | Stifel | Buy → Hold |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Oct-10-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-15-16 | Reiterated | Stifel | Buy |
View All
Exelixis Inc Stock (EXEL) Latest News
Investor Network: Exelixis, Inc. to Host Earnings Call - ACCESS Newswire
Analyst Favorites With Strong Buyback Activity: Exelixis Ranks As a Top Pick - Nasdaq
Ahead of Exelixis (EXEL) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics - Yahoo Finance
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May - Bluefield Daily Telegraph
Exelixis, Inc. (EXEL): Among the Large-Cap Stocks Insiders and Short Sellers Are Dumping Like Crazy - Insider Monkey
BlackRock, Inc. Reduces Stake in Exelixis Inc. - GuruFocus
Here's Why Exelixis (EXEL) is a Strong Momentum Stock - Yahoo Finance
(EXEL) Proactive Strategies - news.stocktradersdaily.com
Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025 - BioSpace
Exelixis to Release First Quarter 2025 Financial Results on Tues - GuruFocus
Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025 | EXEL Stock News - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum? - MSN
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge - ADVFN
Exelixis Reaches Analyst Target Price - Nasdaq
Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release - Yahoo Finance
Expert Outlook: Exelixis Through The Eyes Of 19 Analysts - Benzinga
Citizens JMP reiterates Exelixis stock with $41 target By Investing.com - Investing.com Canada
Citizens JMP reiterates Exelixis stock with $41 target - Investing.com
Exelixis, Inc. (NASDAQ:EXEL) Position Boosted by Summit Investment Advisors Inc. - MarketBeat
Market Participants Recognise Exelixis, Inc.'s (NASDAQ:EXEL) Earnings - simplywall.st
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - Yahoo Finance
(EXEL) Investment Analysis - news.stocktradersdaily.com
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Prostate Cancer Pipeline Analysis and Clinical Trials - openPR.com
Private Sector Steps Up in Cancer Research as Federal Support Wavers - Baystreet.ca
Non-Small-Cell Lung cancer (NSCLC) Pipeline Analysis - openPR.com
Guggenheim maintains Exelixis stock with $42 target By Investing.com - Investing.com India
Guggenheim maintains Exelixis stock with $42 target - Investing.com
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance
Exelixis (EXEL) Gets a Buy from RBC Capital - The Globe and Mail
The Smartest Biotech Stocks to Buy With $50 - The Motley Fool
FY2026 EPS Estimates for Exelixis Lifted by Leerink Partnrs - MarketBeat
Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now? - MSN
Trexquant Investment LP Has $19.82 Million Stake in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Blair William & Co. IL Sells 300,760 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
New Age Alpha Advisors LLC Makes New $2.10 Million Investment in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis Launches Special Equity Award Program - TipRanks
(EXEL) Long Term Investment Analysis - news.stocktradersdaily.com
FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors - MSN
Exelixis Inc Stock (EXEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):